News and Events

October 26, 2022 WEST CHESTER, Pa.--Data will be presented by R Yang and colleagues from the Guangxi Medical University Cancer Hospital and H Gabra from Papyrus Therapeutics Inc demonstrating that intravenously administered rOPCML-Fc has...

March 1, 2022 WEST CHESTER, Pa.--(BUSINESS WIRE)--Papyrus Therapeutics Inc., a biotechnology company pioneering the development of extracellular tumor suppressor therapies, announces the formation of its Scientific Advisory Board [SAB]. James [Jim] B. Lorens Ph.D.,...

January 27, 2022 Papyrus Therapeutics Inc. is delighted to announce that Beth Altman has been appointed to the Board of Directors. Beth Altman, former managing partner at accounting firm KPMG LLP San Diego, has joined Papyrus Therapeutics Inc. as an independent...

August 17, 2021 Papyrus Therapeutics Inc. is delighted to announce that Marc Beer has been appointed as chairman of the Board of Directors. Marc brings more then 30 years of therapeutic development and commercialization experience in biotechnology, pharmaceuticals,...

July 12, 2021 We are pleased to announce that Professor James [Jim] Lorens has joined Papyrus Therapeutics as an independent director of the company.  Jim has wide experience in the academic and biotech sectors and will bring tremendous insight to the...

February 10, 2021 West Chester, Pennsylvania - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has entered into a research collaboration agreement with...